Phase II study of RG-101 and GSK2878175 in patients chronically infected with HCV.

Trial Profile

Phase II study of RG-101 and GSK2878175 in patients chronically infected with HCV.

Suspended
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs GSK 2878175 (Primary) ; RG 101 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 According to a Regulus Therapeutics media release, company received written communication from the U.S. Food and Drug Administration (FDA) to continue clinical hold on RG-101 clinical development program. FDA has requested the final safety and efficacy data from on-going RG-101 studies before reconsidering the clinical hold. Company is planning an additional requests with US FDA to seek the release of the clinical hold.
    • 27 Jun 2016 According to a Regulus Therapeutics media release, the company plans to work with US FDA to seek the release of the clinical hold.
    • 27 Jun 2016 According to a Regulus Therapeutics media release, based on a second serious adverse event (SAE) of jaundice observed from a phase I trial (Profile 266977), the company has received a verbal notice from the U.S. Food and Drug Administration that its Investigational New Drug for RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold and anticipates to receive a formal clinical hold letter from the FDA within 30 days.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top